Format

Send to

Choose Destination
Neurosci Lett. 2019 Jan 19;691:44-50. doi: 10.1016/j.neulet.2018.07.038. Epub 2018 Jul 31.

PET imaging of synaptic density: A new tool for investigation of neuropsychiatric diseases.

Author information

1
PET Center, Department of Radiology and Biomedical Imaging, Yale University, New Haven, CT 06520, USA. Electronic address: jason.cai@yale.edu.
2
PET Center, Department of Radiology and Biomedical Imaging, Yale University, New Haven, CT 06520, USA.

Abstract

Synaptic vesicle glycoprotein 2A (SV2A) is expressed ubiquitously in neurons of the central nervous system, and is the binding target of the anti-epileptic drug levetiracetam. Because of the availability of positron emission tomography (PET) ligands targeting SV2A, there is increasing enthusiasm on the use of SV2A PET to study a variety of neuropsychiatric diseases. This review discusses the recent development of radioligands for PET imaging of SV2A and their potential use in the research and diagnosis of CNS diseases.

KEYWORDS:

Alzheimer’s disease; Autism spectrum disorder; Depression; Epilepsy; Huntington’s disease; Multiple sclerosis; PET; Parkinson’s disease; SV2A; Schizophrenia; Stroke; Synaptic density

PMID:
30075287
PMCID:
PMC6339829
[Available on 2020-01-19]
DOI:
10.1016/j.neulet.2018.07.038

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center